These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24891233)

  • 1. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
    Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
    Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy].
    Iwata N; Yoshida T; Katsuta E; Aoyagi H; Takahata T; Hasegawa K; Kaneko J; Maejima S
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2116-8. PubMed ID: 23267995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
    Crouzet L; Edeline J; Le Du F; Boucher E; Audrain O; Raoul JL
    Acta Oncol; 2012 May; 51(5):687-8. PubMed ID: 22356625
    [No Abstract]   [Full Text] [Related]  

  • 6. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.
    Kim SH; Kim IH; Kim SW; Lee SO
    World J Gastroenterol; 2009 Sep; 15(36):4593-5. PubMed ID: 19777621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
    Okamoto K; Miyoshi K; Murawaki Y
    PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
    Matsumoto K; Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2008 Oct; 20(4):863-72. PubMed ID: 18813828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
    Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma
    Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W
    In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301).
    Inaba Y; Arai Y; Yamaura H; Sato Y; Najima M; Aramaki T; Sone M; Kumada T; Tanigawa N; Anai H; Yoshioka T; Ikeda M;
    Am J Clin Oncol; 2011 Feb; 34(1):58-62. PubMed ID: 20177362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
    Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W
    Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.
    Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V
    World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
    Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
    Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
    Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
    Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal miR-141-3p Induces Gemcitabine Resistance in Biliary Tract Cancer Cells.
    Tokuhisa A; Tsunedomi R; Kimura Y; Nakajima M; Nishiyama M; Takahashi H; Ioka T; Kobayashi S; Eguchi H; Nagano H
    Anticancer Res; 2024 Jul; 44(7):2899-2908. PubMed ID: 38925813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
    Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.